Virus vaccine may be ready for mass production by autumn, Oxford professor says
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
February 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, FEBRUARY 05, 2023
Virus vaccine may be ready for mass production by autumn, Oxford professor says

Coronavirus chronicle

Jason Gale
17 April, 2020, 04:55 pm
Last modified: 17 April, 2020, 05:58 pm

Related News

  • The supply chain crisis opens door to resilience
  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Covid remains a public health emergency, says WHO

Virus vaccine may be ready for mass production by autumn, Oxford professor says

Jason Gale
17 April, 2020, 04:55 pm
Last modified: 17 April, 2020, 05:58 pm
Photo: Bloomberg
Photo: Bloomberg

A coronavirus vaccine trial by the University of Oxford aims to have administered the shot to 500 volunteers by mid-May, Sarah Gilbert, a professor of vaccinology at the university, told the Lancet.

Adults aged 18 to 55 years are being recruited initially in the early- and mid-stage randomized, controlled trial. It will be later extended to older people before an expected phase-3 expansion involving 5,000 volunteers, Gilbert told the medical journal.

"The best-case scenario is that by the autumn of 2020, we have an efficacy result from phase 3 and the ability to manufacture large amounts of the vaccine, but these best-case time frames are highly ambitious and subject to change," Gilbert was quoted as saying.

Gilbert, whose research on vaccines began at the University of Oxford in 1994, was awarded a 2.2 million pound ($2.8 million) grant from the UK's National Institute for Health Research and UK Research and Innovation in March to scale up her team's efforts to move into Covid-19 vaccine research.

Her group's experimental immunization is one of the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others being tested in humans. They are from CanSino Biological Inc./Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc./National Institute of Allergy and Infectious Diseases.

Gilbert's phase 1/2 study aims to split 510 participants into five groups who will be observed for about 6 months with the option for a follow-up visit about a year after entering the trial. One group will receive a second intramuscular shot of the vaccine four weeks after the initial immunization.

The research aims to determine the efficacy, safety and immunogenicity of the candidate vaccine, named ChAdOx1 nCoV-19. A vaccine against meningococcal disease will be given to participants randomly allocated to receive a placebo for control purposes.

Overseas Partners?

Some of the clinical research may need to be undertaken outside the UK if the epidemic there subsides to the point where efficacy can't be reliably determined.

"Our ability to determine vaccine efficacy will be affected by the amount of virus transmission in the local population over the summer, and we are also beginning to think about initiating trials with partners in other countries to increase our ability to determine vaccine efficacy," Gilbert told the Lancet.

Read More: The Drugs and Vaccines That Might End the Coronavirus Pandemic

ChAdOx1 nCoV-19 is a so-called recombinant viral vector vaccine made from a harmless virus -- an adenovirus that has been altered to produce the surface spike protein of the pandemic-causing SARS-CoV-2 virus.

The vaccine acts by priming the immune system to recognize and attack the coronavirus. The vaccine uses the same technique as a vaccine Gilbert's team previously developed for the related MERS coronavirus, which showed promise in animal and early-stage human testing.

The WHO is creating a forum for everyone developing Covid-19 vaccines to share their plans and initial findings, according to Gilbert.

"It is essential that we all measure immunological responses to the various vaccines in the same way, to ensure comparability and generalizability of our collective findings," she said. "Work is continuing at a very fast pace, and I am in no doubt that we will see an unprecedented spirit of collaboration and cooperation, convened by WHO, as we move towards a shared global goal of Covid-19 prevention through vaccination."

Disclaimer: This article first appeared on Bloomberg.com, and is published by special syndication arrangement.

Bloomberg Special / Top News

Coronavirus / Vaccine / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Oil’s New Map: How India turns Russia crude into the west's fuel
    Oil’s New Map: How India turns Russia crude into the west's fuel
  • Photo: Collected
    Adani’s power to come to Bangladesh in first week of March: Nasrul Hamid
  • NBR must increase revenue by working digitally: Tipu Munshi
    NBR must increase revenue by working digitally: Tipu Munshi

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • The supply chain crisis opens door to resilience
  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Covid remains a public health emergency, says WHO

Features

Say it with Colours

Say it with Colours

9h | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

11h | Panorama
Google must adjust to a world where content is increasingly generated by AI. Photo: Bloomberg

Google will join the AI wars, pitting LaMDA against ChatGPT

8h | Panorama
The megaproject Rooppur Nuclear Power Plant has a debt of Tk90,474 crore. Photo: Courtesy

Projects funded with debt need to be selected prudently, and implemented timely

9h | Panorama

More Videos from TBS

ICB to withdraw Padma Bank Investment as return

ICB to withdraw Padma Bank Investment as return

1h | TBS Insight
Kiara Advani & Sidharth Malhotra's Wedding Update

Kiara Advani & Sidharth Malhotra's Wedding Update

1h | TBS Entertainment
US shoots down Chinese spy balloon

US shoots down Chinese spy balloon

13m | TBS World
Lack of coordination, policy biggest problems

Lack of coordination, policy biggest problems

5h | TBS Round Table

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

6
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]